BSEM Share Price Performance
US$5.64
-7.36 (-56.63%)
84.1% undervalued intrinsic discount
US$35.50
Fair Value
Price US$5.64
AnalystConsensusTarget US$35.50
Fair ValueUS$49.56
Share Pricen/a
BioStem Technologies, Inc. Stock Price
- 1 Narratives written by author
- 1 Comments on narratives written by author
- 49 Fair Values set on narratives written by author
BSEM Community Narratives
AN
Fair Value US$49.56 88.6% undervalued intrinsic discount
VENDAJE AC National Launch And BioRetain Data To Drive Future Market Expansion
0users have liked this narrative
1users have commented on this narrative
19users have followed this narrative
VENDAJE AC National Launch And BioRetain Data To Drive Future Market Expansion
Key Takeaways Strategic collaborations and successful CMS partnerships can enhance market adoption and pricing stability, boosting net margins and profitability. Expanding clinical trials and NASDAQ uplisting may increase revenue, earnings, and shareholder value through broader market access and investor reach.Read more
172
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
19users have followed this narrative
AN
US$49.56
88.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
27.09% p.a.
Profit Margin
11.67%
Future PE
13.13x
Price in 2028
US$37.76
Trending Discussion
Recently Updated Narratives
AN
VENDAJE AC National Launch And BioRetain Data To Drive Future Market Expansion
Fair Value: US$49.56 88.6% undervalued intrinsic discount
19 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioStem Technologies, Inc. Key Details
About BSEM
- Founded
- 2006
- Employees
- n/a
- CEO
- WebsiteView website
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
